Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temferon in Glioblastoma Multiforme
NCT03866109Phase 2Terminated
- Sponsor
- Genenta Science
- Start
- Mar 2019
- Primary completion
- May 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Temferon in glioblastoma multiforme (GBM), sponsored by Genenta Science. Primary endpoint: Tolerability and safety of Temferon over the first 90 days. Started Mar 2019; status: terminated.
02
Drugs
Temferon
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT03866109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866109.